Neuvotion announced the commercialisation of its brain-body interface portfolio, timed alongside a clinical study published in Nature Medicine. The platform combines wearable muscle stimulation, spinal neuromodulation, and a minimally invasive BCI to restore movement and sensation after stroke or spinal cord injury. Its first product, the FDA-cleared NeuStim, launches this fall and uses AI-guided electrical stimulation to infer a user's intended movement and assist it.